newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Markets Insider
Zealand Pharma (ZLDPF) announced the presentation of additional data from its Phase 2 ZUPREME-1 trial, evaluating investigational petrelintide.
Petrelintide achieved up to 10.7% mean body weight reduction at 42 weeks versus 1.7% for placebo.
KEY POINTS
88%-98% of participants successfully escalated to the targeted maintenance dose of petrelintide.
Only 1.5% of petrelintide participants discontinued due to gastrointestinal events, with no unexpected safety findings.
Zealand Pharma (ZLDPF) announced the presentation of additional data from its Phase 2 ZUPREME-1 trial, evaluating investigational petrelintide, at the 2026 Scientific Sessions of the American Diabetes Association, taking place in New Orleans, Louisiana. Results from the 42-week, Phase 2 trial show that participants who received once-weekly subcutaneous injections of petrelintide, an amylin analog, achieved clinically meaningful reductions in body weight compared to placebo. Treatment with petrelintide was associated with improvements in cardiometabolic disease risk factors and was well tolerated with rates of gastrointestinal-related adverse events generally similar to placebo. Petrelintide led to mean reductions in body weight from baseline to Week 42 of up to 10.7% vs 1.7% for placebo. In total, 88%-98% of participants successfully escalated to their targeted maintenance dose of petrelintide. Most GI adverse events were mild. Nausea was the most common GI AE, reported for 19.6% of participants on petrelintide vs 6.2% on placebo. Vomiting was rare with petrelintide, while the rates of diarrhea and constipation were similarly low for petrelintide and placebo. Only 1.5% of participants discontinued petrelintide due to gastrointestinal adverse events, and there were no unexpected safety findings. Petrelintide was associated with meaningful improvements in key cardiovascular risk factors, with the reductions with petrelintide ranging from 7.9-10.8cm for waist circumference, 17%-41% for high-sensitivity C-reactive protein and 12%-21% for triglycerides.
Claim 55% Off TipRanks